Tue Jan 11 2022

Key highlights from the study

  • Results showed a 70% decrease in the relative risk of progression to severe respiratory failure and a significant reduction in 28-d mortality with anakinra treatment compared to standard of care.
  • Relative decrease of mortality was 55%, reaching 80% for patients with cytokine storm.
  • Average time until hospital and intensive care unit (ICU) discharge was reduced by one to four days.


From 23 December 2020 to 31 March 2021, 1,060 patients positively diagnosed with Covid-19 were screened, and 594 (excluding those at low risk based on low suPAR results) were randomized at 37 study sites. The SAVE-MORE study, conducted by the Hellenic Institute for the Study of Sepsis, is the first large, pivotal randomized controlled trial to specifically evaluate a patient population triaged, when at risk of progressing to a critical state using suPARnostic®. The study demonstrates the considerable benefit of earlier intervention for the prevention of disease progression and death.

189 patients were allocated to the placebo arm, and 405 patients were allocated to the anakinra arm. Baseline characteristics and co-administered treatments were similar between the two treatment arms. Overall, 91.6% of patients had severe pneumonia as defined by the WHO classification for COVID-19. On day 28, the adjusted proportional odds of having a worse clinical status with anakinra, as compared to placebo, was 0.36. Twenty-eight-day mortality decreased, and hospital stay was shorter.

European Medicines Agency approval

suPAR-measured Kineret treatment is authorised across the EU for COVID-19 in adult patients with pneumonia requiring supplemental oxygen, who are at risk of developing severe respiratory failure.

Administration of the treatment protocol is determined by measuring suPAR levels, which must result in at least 6 ng/mL before initiation.

Kineret is an immunosuppressive drug. It is currently authorised in the EU for the treatment of various inflammatory conditions. In COVID-19 patients, the medicine is considered to reduce the inflammation associated with COVID-19 and thus decrease lower airway damage, preventing development of severe respiratory failure.

Learn more: Kineret | European Medicines Agency (europa.eu)


published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of 4 products:

Quick Triage

A Point of Care Solution


For Automated Systems


Clinical and Research

suPARnostic POC+


Point-of-care finger prick

New Webinar


Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates